药物联合PCI治疗冠状动脉临界狭窄预后及其与血浆hs—CRP、IL—6、IL—8、血浆纤维蛋白原的相关性研究(1)
摘 要：目的 分析药物联合PCI治疗冠状动脉临界狭窄对患者血浆高敏hs-CRP、IL-6、IL-8、血浆纤维蛋白原表达的影响。方法 将在我院接受药物治疗的29例冠状动脉临界狭窄患者设为对照组，将在我院接受药物联合PCI治疗的30例冠状动脉临界狭窄患者设为研究组，检测两组患者治疗前后的血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平。结果 治疗后，研究组患者血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平低于对照组，差异具有统计学意义(P<0.05)。研究组住院期间和出院后1年内的心血管不良事件发生率分别为3.33%和6.67%，低于对照组的20.69%和27.59%，差异具有统计学意义(P<0.05)。结论 药物联合PCI治疗冠状动脉临界狭窄，能够有效降低患者血浆中炎性因子和凝固因子的表达水平，有利于临床进一步改善该疾病患者的预后。
关键词：冠状动脉临界狭窄；药物；PCI；炎性因子；凝固因子
中图分类号：R543.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.033
, http://www.100md.com
文章编号：1006-1959(2018)13-0112-03
Abstract：Objective To analyze the effect of drug combined with PCI on coronary artery stenosis on plasma high-sensitivity hs-CRP， IL-6，IL-8 and plasma fibrinogen expression.Methods 29 patients with coronary artery stenosis who were treated with drugs in our hospital were enrolled in the control group.30 patients with coronary artery stenosis who underwent drug-assisted PCI in our hospital were enrolled in the study group.Plasma levels of hs-CRP，IL-6，IL-8 and fibrinogen were measured before and after treatment in both groups.Results After treatment，the levels of plasma hs-CRP，IL-6，IL-8 and fibrinogen in the study group were lower than those in the control group，the difference was statistically significant(P<0.05).The incidence of cardiovascular adverse events in the study group during the hospitalization period and within 1 year after discharge was 3.33% and 6.67%，respectively，which was lower than the control group's 20.69% and 27.59%，the difference was statistically significant(P<0.05).Conclusion The combination of drugs and PCI in the treatment of coronary artery stenosis can effectively reduce the expression levels of inflammatory factors and coagulation factors in patients' plasma，which is beneficial to further improve the prognosis of patients with this disease.
, 百拇医药
Key words：Coronary artery stenosis；Drugs；PCI；Inflammatory factors；Coagulation factors
冠狀动脉临界狭窄(coronary artery stenosis)是指冠状动脉造影直径法检测狭窄程度为50%～70%的病变，又被我国临床称为中等程度狭窄[1]。现阶段，国内外对于该疾病应该采取何种方法治疗尚无明确定论，多主张通过对患者心肌血流动力学及斑块性质进行分析来制定相应的治疗方案[2]。但目前我国较大一部分基层医院尚未开展心肌血流分析技术、光学相干断层成像技术，故较难开展冠状动脉临界狭窄的临床治疗，需要寻找其他方法来评价患者的疾病风险及预后[3]。我院本次研究通过对比药物治疗及药物联合PCI治疗冠状动脉临界狭窄对患者血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平的影响，了解何种方法更适用于冠状动脉临界狭窄患者的临床治疗，分析上述指标在评价该疾病患者预后中的应用价值。
1资料与方法
1.1一般资料 将2015年2月～2016年1月在江西鹰潭市人民医院接受药物治疗的29例冠状动脉临界狭窄患者设为对照组，将在我院接受药物联合PCI治疗的30例冠状动脉临界狭窄患者设为研究组，本研究经医院伦理会批准。研究组中，男16例，女14例，年龄36～72岁，平均年龄(53.81±2.26)岁。对照组中，男17例，女12例，年龄35～74岁，平均年龄(54.81±2.35)岁。两组患者的性别、年龄等一般资料比较，差异无统计学意义(P>0.05)，均衡可比。, 百拇医药(郑晓芳)
关键词：冠状动脉临界狭窄；药物；PCI；炎性因子；凝固因子
中图分类号：R543.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.033
, http://www.100md.com
文章编号：1006-1959(2018)13-0112-03
Abstract：Objective To analyze the effect of drug combined with PCI on coronary artery stenosis on plasma high-sensitivity hs-CRP， IL-6，IL-8 and plasma fibrinogen expression.Methods 29 patients with coronary artery stenosis who were treated with drugs in our hospital were enrolled in the control group.30 patients with coronary artery stenosis who underwent drug-assisted PCI in our hospital were enrolled in the study group.Plasma levels of hs-CRP，IL-6，IL-8 and fibrinogen were measured before and after treatment in both groups.Results After treatment，the levels of plasma hs-CRP，IL-6，IL-8 and fibrinogen in the study group were lower than those in the control group，the difference was statistically significant(P<0.05).The incidence of cardiovascular adverse events in the study group during the hospitalization period and within 1 year after discharge was 3.33% and 6.67%，respectively，which was lower than the control group's 20.69% and 27.59%，the difference was statistically significant(P<0.05).Conclusion The combination of drugs and PCI in the treatment of coronary artery stenosis can effectively reduce the expression levels of inflammatory factors and coagulation factors in patients' plasma，which is beneficial to further improve the prognosis of patients with this disease.
, 百拇医药
Key words：Coronary artery stenosis；Drugs；PCI；Inflammatory factors；Coagulation factors
冠狀动脉临界狭窄(coronary artery stenosis)是指冠状动脉造影直径法检测狭窄程度为50%～70%的病变，又被我国临床称为中等程度狭窄[1]。现阶段，国内外对于该疾病应该采取何种方法治疗尚无明确定论，多主张通过对患者心肌血流动力学及斑块性质进行分析来制定相应的治疗方案[2]。但目前我国较大一部分基层医院尚未开展心肌血流分析技术、光学相干断层成像技术，故较难开展冠状动脉临界狭窄的临床治疗，需要寻找其他方法来评价患者的疾病风险及预后[3]。我院本次研究通过对比药物治疗及药物联合PCI治疗冠状动脉临界狭窄对患者血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平的影响，了解何种方法更适用于冠状动脉临界狭窄患者的临床治疗，分析上述指标在评价该疾病患者预后中的应用价值。
1资料与方法
1.1一般资料 将2015年2月～2016年1月在江西鹰潭市人民医院接受药物治疗的29例冠状动脉临界狭窄患者设为对照组，将在我院接受药物联合PCI治疗的30例冠状动脉临界狭窄患者设为研究组，本研究经医院伦理会批准。研究组中，男16例，女14例，年龄36～72岁，平均年龄(53.81±2.26)岁。对照组中，男17例，女12例，年龄35～74岁，平均年龄(54.81±2.35)岁。两组患者的性别、年龄等一般资料比较，差异无统计学意义(P>0.05)，均衡可比。, 百拇医药(郑晓芳)